

UPN0003-100

PATENT

## REMARKS

The Examiner required Applicant to elect one of 8 allegedly patentably distinct inventions for examination. Group I, encompassing claims 1-32 and 53-60, is said to be "drawn to a pharmaceutical composition, classified in class 530, subclass 300." Group II, encompassing claim 33-39, is said to be "drawn to methods of treatment of heart diseases or stroke or blood vessel blockage, classified in class 514, subclass 2+." Group III, encompassing claims 40-53, is said to be "drawn to a method of identifying compounds that modulate binding of Ang-1 to ECM, classified in class 435, subclass 7.1" Group IV, encompassing claim 63, is said to be "drawn to a method of preventing diabetes, classified in class 514, subclass 12." Group V, encompassing claims 64-66 and 75-77, is said to be "drawn to a fusion protein, classified in class 424, subclass 192.1" Group VI, encompassing claims 67-68, is said to be "drawn to a method of diagnosing, classified in class 435, subclass 6+." Group VII, encompassing claims 69-74 is said to be "drawn to a method of inhibiting, classified in class 435, subclass 7.2" Group VIII, encompassing claims 78-80, is said to be "drawn to a nucleic acids, classified in class 536, subclasses 23.1." Applicant respectfully traverses and request reconsideration of the Restriction Requirement.

Applicant provisionally elects herein Group I. Applicants note the Examiner did not place claims 61 and 62 in any of the 8 groups. Applicants, accordingly, conclude that they can be included in any group for examination and request that claims 61 and 62 be added into Group I and be examined.

The Examiner also alleges that Applicant is required to elect one sequence for examination and that it is not an election of species since each of the "compounds is not a member of a single genus." (Office Action, page 3). Applicants provisionally elect SEQ ID NO: 1 solely for the purpose of complying with the Examiner's requirement.

Applications respectfully request that the Examiner reconsider the election as an election of species for the purposes of claim 1 and SEQ ID NOs: 1-4. The sequences of SEQ ID NOs:1-4 are members of a single genus. The genus is defined as "an ECM-

UPN0003-100

PATENT

binding fragment of Ang-1." SEQ ID NOs:1-4 comprise amino acid sequences that are fragments of Ang-1 and are capable of binding to the extracellular matrix (ECM). Accordingly, the sequences are all members of a single genus and should be examined as such.

In view of the foregoing, Applicants request that claims 61 and 62 be included in Group I since they were not included in the restriction requirement and that the election of SEQ ID NO: 1 be construed as an election of species since the sequences listed in claim 1 are members of a single genus.

**Conclusion**

The examination of these claims and passage to allowance are respectfully requested. An early Notice of Allowance is therefore earnestly solicited. Applicants invite the Examiner to contact the undersigned at (215) 665-6928 to clarify any unresolved issues raised by this response.

Respectfully submitted,



Mark DeLuca  
Registration No. 33,229

Date: October 28, 2005

COZEN O'CONNOR  
1900 Market Street  
Philadelphia, PA 19103  
Telephone: 215.665.5592  
Facsimile: 215.665.2013